Semaglutide/Tirzepatide + Tesamorelin Weight Loss Stack

This weight loss stack combines GLP-1 receptor agonist therapy (semaglutide or tirzepatide) with the growth hormone-releasing hormone analog tesamorelin to achieve fat loss through complementary mechanisms: appetite suppression and metabolic rate modulation from the GLP-1 agonist, plus targeted visceral fat reduction and improved body composition from tesamorelin's GH-releasing activity.

Quick Comparison

Property	peptide	The Weight Loss Stack: Semaglutide/Tirzepatide + Tesamorelin
Source	Salmon DNA fragments	Various sources
Primary Mechanism	A2A receptor activation, DNA repair	Varies by ingredient
Key Benefits	Tissue regeneration, anti-inflammation, collagen boost	Multiple skin benefits
Best Time to Apply	AM or PM	AM or PM
Can Combine?	Generally compatible — check specific guidelines.

How to Use Together

Semaglutide: titrate from 0.25 mg weekly SC injection, increasing every 4 weeks through 0.5 mg, 1.0 mg, 1.7 mg, to a maximum of 2.4 mg weekly as tolerated. OR Tirzepatide: titrate from 2.5 mg weekly SC injection, increasing every 4 weeks through 5 mg, 7.5 mg, 10 mg, 12.5 mg, to a maximum of 15 mg weekly. Tesamorelin: 2 mg daily SC injection, administered in the evening (aligning with the natural nocturnal GH pulse). Begin tesamorelin after reaching a stable GLP-1 agonist dose (usually 4-8 weeks into titration) to avoid confounding side effects during the GLP-1 titration phase.

Protein intake is critical during this protocol — aim for 1.2-1.6 g/kg of ideal body weight daily to mitigate the lean mass loss associated with GLP-1-mediated weight loss. Resistance training 2-3 times weekly further preserves lean mass and amplifies tesamorelin's body composition benefits.

Safety Notes

Both semaglutide/tirzepatide and tesamorelin are FDA-approved medications with well-characterized safety profiles from large clinical trials. GLP-1 agonist side effects include nausea, vomiting, diarrhea (especially during titration), and rare but serious risks including pancreatitis, gallbladder disease, and medullary thyroid carcinoma (contraindicated in patients with MEN2 or family history of medullary thyroid cancer). Tesamorelin can cause peripheral edema, joint pain, and transient glucose elevation. Combining a GLP-1 agonist with a GH-releasing agent has not been studied in controlled trials — the combination is off-label. Tesamorelin's GH release could theoretically worsen insulin resistance in some individuals, potentially counteracting the GLP-1 agonist's glucose-lowering effect. Monitor fasting glucose and HbA1c regularly. This stack requires prescription and medical supervision — it is not appropriate for self-directed use without physician oversight.

Recommended Products (3)

All Products →

glp 1-analog

Semaglutide

Ozempic / Wegovy / Rybelsus

Long-acting GLP-1 receptor agonist — FDA-approved for type-2 diabetes and chronic weight management, landmark for its ~15% mean weight reduction in STEP trials.

Ozempic: 0.25–2 mg weekly; Wegovy: up to 2.4 mg weeklyFDA-approved (Ozempic, Wegovy, Rybelsus)

growth hormone-secretagogue

Tesamorelin

Egrifta

FDA-approved synthetic GHRH analog indicated for HIV-associated lipodystrophy, studied for visceral adipose tissue reduction and cognitive endpoints.

2 mg per daily dose (per FDA labeling)FDA-approved (Egrifta)

tirzepatide class

Tirzepatide

Mounjaro / Zepbound

First-in-class dual GIP/GLP-1 receptor agonist — SURMOUNT trials showed ~20% mean weight reduction and superior A1c control versus semaglutide.

2.5–15 mg weekly (escalating)FDA-approved (Mounjaro T2D, Zepbound obesity)

Semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro/Zepbound) are FDA-approved peptide medications that have demonstrated 15-22% total body weight loss in pivotal clinical trials. They work primarily through central appetite suppression (hypothalamic GLP-1 receptor activation), delayed gastric emptying, and improved insulin sensitivity. Tirzepatide adds GIP receptor agonism, which may explain its slightly superior weight loss efficacy compared to semaglutide in head-to-head data.

Tesamorelin is an FDA-approved GHRH analog that stimulates pulsatile growth hormone release from the anterior pituitary. It was originally approved for HIV-associated lipodystrophy, specifically for reducing visceral adipose tissue (VAT). In clinical trials, tesamorelin reduced trunk fat by 15-18% without the metabolic side effects of exogenous GH. The rationale for combining it with a GLP-1 agonist is body composition optimization: GLP-1 agonists reduce total body weight but also cause some lean mass loss (approximately 25-40% of weight lost is lean mass). Tesamorelin's GH-mediated effects promote lipolysis while preserving lean mass, potentially improving the fat-to-lean ratio of the weight lost.

Frequently Asked Questions

Why add tesamorelin to semaglutide — isn't semaglutide enough for weight loss?

Semaglutide alone produces substantial weight loss (15-17% in clinical trials). The rationale for adding tesamorelin is body composition optimization, not additional scale weight loss. GLP-1 agonists cause significant lean mass loss alongside fat loss. Tesamorelin's GH-mediated effects preferentially mobilize visceral fat while preserving lean tissue, potentially improving the quality of weight loss rather than the quantity.

Should I choose semaglutide or tirzepatide for this stack?

Tirzepatide has demonstrated slightly superior weight loss efficacy in clinical trials (20-22% vs 15-17% for semaglutide) due to its dual GLP-1/GIP receptor agonism. However, individual response varies, and some patients tolerate one better than the other. Cost, insurance coverage, and availability are also practical considerations. Both are valid choices for this stack.

Will the GH from tesamorelin cause side effects like exogenous GH?

Tesamorelin stimulates physiological, pulsatile GH release from your own pituitary — it does not provide a constant supraphysiological GH level like exogenous GH injections. This pulsatile pattern produces fewer side effects (less water retention, less insulin resistance, less joint pain) than equivalent GH doses from direct injection. However, some GH-related effects (mild edema, joint stiffness) can still occur.

How important is resistance training during this protocol?

Critical. GLP-1 agonist-induced weight loss includes 25-40% lean mass loss without exercise intervention. Resistance training 2-3 times weekly can reduce lean mass loss to 10-20% of total weight lost. Combined with tesamorelin's GH effects and adequate protein intake (1.2-1.6 g/kg), resistance training is the most important modifiable factor for body composition during this protocol.

How long can I stay on this stack?

Semaglutide and tirzepatide are approved for indefinite use — weight regain after discontinuation is well-documented (approximately two-thirds of lost weight regained within one year of stopping). Tesamorelin is typically cycled: 3-6 months on, 1-3 months off, to avoid tachyphylaxis (reduced pituitary responsiveness) and to monitor for metabolic effects. The GLP-1 agonist can continue during tesamorelin off-cycles.

Is this stack appropriate for someone who is not obese?

GLP-1 agonists for weight loss are FDA-approved for BMI ≥30 or BMI ≥27 with at least one weight-related comorbidity. Using them for modest weight loss in normal-weight individuals is off-label, carries the same side effect risks, and raises concerns about lean mass loss in individuals who cannot afford to lose muscle. Tesamorelin is FDA-approved specifically for HIV lipodystrophy. Discuss appropriateness with your physician.

Other peptide Ingredient Combinations

The Anti-Aging Stack: GHK-Cu + Epitalon

GHK-Cu and Epitalon target two distinct hallmarks of aging — extracellular matrix degradation and te…

The Athletic Performance Stack: IGF-1 LR3 + Ipamorelin + BPC-157

The athletic performance stack layers three peptides with distinct but complementary mechanisms to s…

The Cognitive Stack: Semax + Selank

The classic Russian nootropic peptide pairing. Semax (an ACTH 4-10 analog) enhances BDNF expression …

The Fat Loss Stack: Tesamorelin + CJC-1295/Ipamorelin

Tesamorelin and CJC-1295/Ipamorelin both target the GH axis but through complementary timing and rec…

The GH Stack: CJC-1295 + Ipamorelin

The dual-pathway growth-hormone stack. CJC-1295 (GHRH analog) opens the pituitary somatotroph; Ipamo…

The Gut Healing Stack: BPC-157 + KPV + Larazotide

The gut healing stack combines three peptides targeting distinct aspects of intestinal repair: BPC-1…

The Healing Stack: BPC-157 + TB-500

The canonical regenerative-peptide pairing. BPC-157 and TB-500 operate through non-overlapping biolo…

Immune Support Stack

A combination approach targeting immune function through three complementary mechanisms: adaptive im…

The Joint Repair Stack: BPC-157 + Pentosan Polysulfate + TB-500

A comprehensive joint-repair protocol targeting all layers of joint pathology: BPC-157 for periartic…

The Longevity Stack: Epitalon + MOTS-c + SS-31

Three peptides targeting different hallmarks of aging: Epitalon for telomerase activation and pineal…

The Metabolic Stack: GLP-1 + GHS

A newer 'metabolic recomposition' pairing some practitioners use: a GLP-1 agonist for appetite and t…

The Nootropic Stack: Semax + Selank + GH-Axis Support

A three-tier nootropic peptide stack targeting cognitive performance through complementary mechanism…

The Sexual Health Stack: PT-141 + Kisspeptin-10

PT-141 and Kisspeptin-10 target complementary aspects of sexual function — central desire pathways a…

The Skin Rejuvenation Stack: GHK-Cu + GH-Axis + Collagen

A multi-level skin rejuvenation protocol combining topical signaling (GHK-Cu), systemic GH-axis elev…

The Sleep Stack: DSIP + Ipamorelin

DSIP (Delta Sleep-Inducing Peptide) and ipamorelin target complementary aspects of sleep optimizatio…

Browse All peptide Products